Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Non-Current Liabilities (2023 - 2025)

Krystal Biotech (KRYS) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $110.5 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 2.29% to $110.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $110.5 million through Dec 2025, up 2.29% year-over-year, with the annual reading at $110.5 million for FY2025, 2.29% up from the prior year.
  • Total Non-Current Liabilities hit $110.5 million in Q4 2025 for Krystal Biotech, up from $99.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $110.5 million in Q4 2025 to a low of $39.7 million in Q4 2023.
  • Historically, Total Non-Current Liabilities has averaged $89.2 million across 3 years, with a median of $95.3 million in 2024.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 172.04% in 2024 and later grew 2.29% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $39.7 million in 2023, then skyrocketed by 172.04% to $108.0 million in 2024, then increased by 2.29% to $110.5 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for KRYS at $110.5 million in Q4 2025, $99.1 million in Q3 2025, and $95.0 million in Q2 2025.